Svetlana A. Kulyova

Svetlana A. Kulyova

Auto-generated profile, based on publicly available information

Svetlana A. Kulyova

N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia; Saint Petersburg State Pediatric Medical University, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2022 in Voprosy onkologii
Verified
Journal Article
Open access
PDF file
РХРина Хабарова
Рина Хабарова
СКСветлана Кулева
Светлана Кулева
Introduction. А decade ago, the artificial intelligence (AI), in particular, neural networks (NN), as a diagnostic opportunity in medical practice, seemed only a distant prospect. Nowadays, the AI is an increasingly popular and daily improving approach in all aspects of clinical and fundamental medicine. Purpose of the research: development of NN and training it to recognize four types of benign melanocytic skin lesions, and integration of the AI into a mobile application. Material and Methods. Clinical and dermatoscopic examination of skin lesions was carried out in 600 pediatric patients. Tumors were removed and pathomorphologically verified in 65 cases. Dermal nevus was found in 43% (n=28), compound nevus ― in 33.8% (n=22), pyogenic granuloma ― in 10.8% (n=7), Spitz-nevus ― in 6.2% (n=4), blue nevus ― in 3.1% (n=2), and melanoma ― in 3.1% (n=2). Seven patients with pyogenic granulomas and two patients with melanoma were excluded from the test set during NN training. Augmentation has been carried out in the training set, therefore, the database has been increased from 600 images to 1800. The NN has been written in the machine language Python with the use of the machine learning framework TensorFlow 2.0. The network architecture is based on the pre-trained model «EfficientNet B7» with the use of «supervised learning» paradigm. Results. After a period of learning, an accuracy up to 83% in determining /of the four types of melanocytic nevi has been achieved on the test set. Despite the limited sampling, sensitivity of the method, depending on the type of the lesion, was 100% (for blue nevus), 73% (compound nevus), 93% (dermal nevus), and 75% (Spitz-nevus);& The specificity was 98, 94, 82 and 98% respectively. Along with development and learning, the AI has been integrated into the mobile appication «KIDS NEVI» to provide practical usiage of the method. Conclusion. The AI has demonstrated high potential as an auxiliary method for diagnosing melanocytic skin tumors in children and adolescents. Significant achievements in informative value have been presented despite the limited sample size. Введение. Десятилетие назад искусственный интеллект (ИИ), в частности нейронные сети (НС), как диагностическая опция в практике врача казался лишь отдаленной перспективой. На сегодняшний день применение ИИ во всех сферах клинической и фундаментальной медицины является все более востребованным и ежедневно совершенствующимся подходом. Цель исследования. Разработка НС и ее обучение распознаванию четырех типов доброкачественных меланоцитарных новообразований кожи, интеграция искусственного интеллекта в мобильное приложение. Материал и методы. 600 пациентам детского возраста были проведены клиническое и дерматоскопическое исследования новообразований кожи. У части пациентов (n=65) элементы были удалены и патоморфологически верифицированы. В 43% (n=28) был выявлен дермальный невус, в 33,8% (n=22) ― сложный невус, в 10,8% (n=7) ― пиогенная гранулема, в 6,2% (n=4) ― невус Шпиц, по 3,1% (n=2) были вариантами голубой невус и меланома кожи. Семь пациентов с пиогенными гранулемами и 2 с меланомой были исключены из тестовой выборки во время обучения НС. В обучающей выборке была проведена аугментация, тем самым, база была увеличена с 600 до 1800 изображений. НС написана на языке программирования Python с использованием фрэймворка для машинного обучения TensorFlow 2.0. Архитектура сети основана на предварительно обученной модели «EfficientNet B7» с применением парадигмы «обучения с учителем». Результаты. После периода обучения на тестовой когорте достигнута 83 % точность распознавания четырех типов меланоцитарных невусов. Несмотря на ограниченную выборку, чувствительность метода в зависимости от класса новообразования составила 100% (голубой невус), 73% (сложный невус), 93% (дермальный невус) и 75% (невус Шпиц), специфичность ― 98, 94, 82 и 98% соответственно. Помимо разработки и обучения искусственный интеллект интегрирован в мобильное приложение «KIDS NEVI», что обеспечило практическое применение метода. Заключение. ИИ в качестве вспомогательного метода диагностики меланоцитарных новообразований кожи у детей и подростков продемонстрировал высокий потенциал. Несмотря на ограниченную выборку, в настоящем исследовании...

1 January 2017 in Oncopediatrics
Verified
Journal Article
Open access
PDF file
SKS. A. Kulyova
S. A. Kulyova
EIEvgeny N. Imyanitov
Evgeny N. Imyanitov
Опухоль Вильмса: синдромальная и молекулярная диагностика

23 May 2011 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
SKSvetlana A. Kulyova
Svetlana A. Kulyova
BKBoris A. Kolygin
Boris A. Kolygin
Purpose. Prospective analysis of the efficacy of the original protocol SPbHL-05 was performed.Patients and Methods. Sixty patients with Hodgkin's lymphoma (HL) aged less than 18 years old were treated in accordance with SPbHL-05 from January 2000, to July 2009. In induction chemotherapy we used VBVP and ABVD schedules followed by involved-field radiotherapy. Fourteen patients (23,3%) with 0–2 adverse factors (the favourable group) received two cycles of chemotherapy (VBVP), 25 children (41,7%) with 3-4 unfavorable signs (the intermediate group) received two cycles of VBVP alternating with two cycles of ABVD, 21 patient (35%) who had 5 or more adverse prognostic factors (the unfavourable group) received three cycles of VBVP alternating with three cycles of ABVD.Results. With a median follow-up of 68 months, overall survival (OS) at 5 years is 91.3%, event-free survival (EFS) is 82.8%. OS in the favourable and intermediate risk group were 100%, EFS were 92,9% and 90,7%, respectively, OS and EFS in unfavourable risk group—77,1% and 55,6%, respectively.Conclusion. The identification of prognostic risk factors and using medicines with less prominent side effects would be of major importance in the development of new strategies of treatment for childhood HL.

9 August 2024 in Russian Journal of Pediatric Hematology and Oncology
Verified
Journal Article
Open access
PDF file
SKS. A. Kulyova
S. A. Kulyova
SVS. R. Varfolomeeva
S. R. Varfolomeeva
KKKirill Kirgizov
Kirill Kirgizov
EPElizaveta Prosekina
Elizaveta Prosekina
ORO. M. Romantsova
O. M. Romantsova
TGT. V. Gorbunova
T. V. Gorbunova
Introduction. Tumor-associated gangliosides are overexpressed on a large number of tumors. The ratio of the amount of gangliosides varies from one type of tumor to another. Tissue restriction of GD2 expression in normal cells and its presence in a wide range of human tumor diseases has increased the relevance of GD2 as a target for immunooncology drugs.The aim of the study was to improve the efficacy of the treatment of children and adolescents with refractory and recurrent solid malignancies (soft tissue, undifferentiated and bone sarcomas) by incorporating targeted immunotherapeutic options (passive immunotherapy with antiGD2 monoclonal antibodies (MA)) into comprehensive therapy programs.The primary objective of the study was to analyze the efficacy of tandem use of antiGD2 MA and 2+ line chemotherapy on survival. Secondary targets were overall response rate (complete remission (CR) + partial remission (PR)), tumor control rate (CR + PR + stabilization), duration of response, and immune-associated adverse events.Materials and methods. The clinical study protocol was initiated at the Petrov National Medical Research Center of Oncology of the Ministry of Health of Russia and approved by the local ethics committee No. 8 of 21.05.2021. On the basis of a signed memorandum of cooperation, the Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov at N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia.The study is prospective. It is planned to evaluate the efficacy and safety of using antiGD2 MA and 2+ line chemotherapy at the investigator's choice in patients under 18 years of age with bone, soft tissue and undifferentiated sarcomas with positive GD2 expression and disease progression/recurrence on/after the 1st line of polychemotherapy.This study screened 40 patients to randomize 10 patients. In the future, an additional set of patients is planned.Conclusion. Based on the results obtained, the efficacy and safety of using a combination of antiGD2 immunotherapy and 2+ line chemotherapy in patients under 18 years of age with refractory and recurrent forms of bone and soft-tissue GD2-positive sarcomas will be concluded.

17 April 2023 in Russian Journal of Pediatric Hematology and Oncology
Verified
Journal Article
Open access
PDF file
SKS. A. Kulyova
S. A. Kulyova
AAA. A. Abadjeva
A. A. Abadjeva
EME. A. Mikhailova
E. A. Mikhailova
MKM. A. Kulyov
M. A. Kulyov
YFYu. G. Fedukova
Yu. G. Fedukova
ЮФЮ. Г. Федюкова
Ю. Г. Федюкова
Currently, the use high doses chemotherapy (HDC) supported by autologous peripheral blood stem cells in consolidation is a necessary therapeutic option in patients with high-risk neuroblastoma (NB). Conditioning regimens and schemes of HDC remain the subject of debate. In recent years, the evidence base of the advantages of tandem myeloablative procedures in comparison with single-transplantation has been actively accumulated in clinical practice. This article presents our own experience of tandem-transplantation with stem cell rescue in the N.N. Petrov National Medical Research Centre of Oncology (Saint-Petersburg) in four patients with initially stratified high-risk group NB; two of them were NMYC amplified. Tandem consolidation included TC ([T]hiotepa, [C]yclophosphamide) and CEM ([C]arboplatin, [E]toposide, [M]elphalan) regimens. The acceptable toxicity of the tandem-transplantation is proved.

30 June 2023 in Voprosy onkologii
Verified
Journal Article
Open access
PDF file
СКСветлана Кулева
Светлана Кулева
КБКсения Борокшинова
Ксения Борокшинова
ИБИрина Балдуева
Ирина Балдуева
ТНТатьяна Нехаева
Татьяна Нехаева
AAAnna Artemyeva
Anna Artemyeva
ГСГазиз Сахаутдинов
Газиз Сахаутдинов
Diffuse high-grade glioma is the most common highly malignant primary brain tumor with an extremely aggressive growth and an unfavorable prognosis. The article describes a clinical case of a 10-year-old child with diffuse midline glioma, H3 K27M-mutant, who after standard chemoradiotherapy is designed as a maintenance therapy for a dendritic cell vaccine based on immunogenic carcinotesticular and GD2 antigens (CTA+ (cancer-testis antigen) GD2+ (ganglioside) vaccine). Tumor lysate was represented by glioblastoma cell culture with 96% GD2 expression. GM-CSF (granulocyte-macrophage colony-stimulating factor), IL4 (interleukin 4) and FNOα (tumor necrosis factor α) were used as the growth and differentiation factors of dendritic cells derived from peripheral blood monocytes. Multitargeted immunotherapy with CTA+GD2+ vaccine apriori solves the evolution problem of phenotypic heterogeneity and has greater clinical and immunological efficacy in high-grade gliomas with their gradual immunoediting. Диффузная глиома высокой степени злокачественности (high-grade глиома) — наиболее часто встречающаяся высокозлокачественная первичная опухоль головного мозга с крайне агрессивным течением и неблагоприятным прогнозом. В статье описывается клинический случай 10-летнего ребенка с диффузной срединной глиомой головного мозга с альтерацией в гене H3 K27, которому после стандартного химиолучевого лечения в качестве поддерживающей терапии создан дендритноклеточный вакцинный препарат на основе иммуногенных раковотестикулярных и GD2 антигенов [(CTA+ (cancer-testis antigen) GD2+ (ganglioside)] вакцина). Опухолевый лизат был представлен глиобластомной клеточной культурой с экспрессией GD2 96%. В качестве ростовых и дифференцировочных факторов дендритных клеток, полученных из моноцитов периферической крови, были ГМ-КСФ (гранулоцитарно-макрофагальный колониестимулирующий фактор), ИЛ4 (интерлейкин 4) и ФНОα (фактор некроза опухоли α). Мультитаргетная иммунотерапия CTA+GD2+ аутологичной ДК-вакциной априори решает эволюционную проблему фенотипической гетерогенности и обладает большей клинической и иммунологической эффективностью в отношении high-grade глиом с их постепенным иммуноредактированием.